ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Bayer HealthCare Commemorates Fourth Anniversary of its Master Agreement with University of California, San Francisco

January 8, 2015 – 6:00 am | Edit Post
Bayer HealthCare Commemorates Fourth Anniversary of its Master Agreement with University of California, San Francisco

Three UCSF researchers are partnering with Bayer HealthCare in this unique academic-industry collaboration

SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ — Bayer HealthCare today announced three research collaborations established under its master agreement with University of California, San Francisco (UCSF). Since the launch of the master agreement in 2011, Bayer HealthCare has formed collaborative research projects with UCSF’s Charles Craik, Ph.D., Andrej Sali, Ph.D. and Robert Stroud, Ph.D. The focus of these collaborations between UCSF and Bayer HealthCare is to expedite the identification of potential therapeutic targets and development of drug discovery tools.

Bayer has established research projects with the following UCSF scientists:

  • Charles Craik, Ph.D., professor at UCSF and Bayer HealthCare scientists are examining the application of protease substrate profiling libraries for the identification of novel drug targets for NETosis in inflammatory and immune disorders.
  • Andrej Sali, Ph.D., professor at UCSF and Bayer HealthCare researchers are using computational modelling to predict and optimize the immunogenicity of therapeutic proteins, such as the therapies used to treat hemophilia A.
  • Robert Stroud, Ph.D., head of UCSF’s Membrane Protein Expression Center is working with Bayer HealthCare to express and purify a key metabolic transporter, focused on the field of oncology.

These three research collaborations were established with the goal to facilitate an efficient and productive pathway to accelerate research progress in this public-private agreement.

“On the fourth anniversary of this collaboration with UCSF, the joint efforts of Bayer’s scientists and Dr. Craik, Dr. Sali and Dr. Stroud have demonstrated how research can be extremely productive when top scientists from academia and industry collaborate closely,” said Christopher Haskell, Ph.D., head of the U.S. Science Hub at Bayer HealthCare. “Even in such a short period of time, our collaboration with Dr. Craik has resulted in a published paper in 2013, with other research discoveries on the horizon. We are excited to continue our collaboration with top scientists at UCSF.”

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

About Bayer in the Bay Area
Bayer HealthCare is the third largest biotech employer in the Bay Area and a global leader in the research, development and manufacturing of biotechnology and specialty pharmaceutical therapies that improve human health. Bayer HealthCare’s presence on the U.S. West Coast includes a manufacturing facility in Berkeley and its U.S. research hub, the U.S. Innovation Center in San Francisco. 

© 2015 Bayer HealthCare
BAYER and the Bayer Cross are registered trademarks of Bayer.

Our online press service is just a click away: press.healthcare.bayer.com
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Logo – http://photos.prnewswire.com/prnh/20140312/NY79226LOGO

SOURCE Bayer HealthCare

Veracyte to Present at the J.P. Morgan 33rd Annual Healthcare Conference

January 8, 2015 – 5:30 am | Edit Post
Veracyte to Present at the J.P. Morgan 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2015 /PRNewswire/ — Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the J.P. Morgan 33rd Annual Healthcare Conference on Thursday, January 15, 2015, at 8:30 a.m. Pacific Time in San Francisco, Calif.

The live audio webcast and subsequent replay may be accessed by visiting Veracyte’s website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 14 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 140 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company is in late product development for a genomic test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases that include idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:
Tracy Morris
650-380-4413 
Tracy.Morris@Veracyte.com

Investors:
Ami Bavishi
Burns McClellan, Inc.
212-213-0006
abavishi@burnsmc.com   

 

SOURCE Veracyte

Aethlon Medical to Present at Biotech Showcase 2015

January 8, 2015 – 5:15 am | Edit Post
Aethlon Medical to Present at Biotech Showcase 2015

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ — Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the Biotech Showcase 2015 Conference on Wednesday, January 14, 2015.  Details of Aethlon Medical’s presentation are as follows:

Event:

Biotech Showcase 2015

Date:

Wednesday, January 14, 2015

Time:

4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time

Location:

Parc 55 Wyndham Union Square, San Francisco, CA

A live audio webcast of the presentation will be available on the Company’s website (www.aethlonmedical.com) in the Investor Relations section on the Events and Presentations or can be accessed directly at http://edge.media-server.com/m/p/4cvayawf. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About Biotech Showcase 2015
The Biotech Showcase 2015 conference takes place January 12-14, 2015, at the Parc 55 Wyndham Hotel located in Union Square, San Francisco, California. Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders.  The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.  Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.  For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Aethlon Media Contact:
Leah-Michelle Nebbia (for interviews requests)
Golin
202-585-2651
lnebbia@golin.com

James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com 

Photo – http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 

SOURCE Aethlon Medical, Inc.

Illumina to Consolidate Bay Area Operations at New Campus

January 7, 2015 – 5:54 pm | Edit Post

BioMed Realty Trust Inc. announced Monday that Illumina Inc. signed a 15-year lease for a new campus in Foster City.

GlySens Raises $12M for Wireless Implantable Glucose Sensor

January 7, 2015 – 5:33 pm | Edit Post

San Diego-based GlySens says it has raised $12 million in Series C funding to advance its wireless technology for an implantable sensor that could be used to monitor blood sugar levels in people with…

[[Click headline to continue reading.]]

GlySens Raises $12M for Wireless Implantable Glucose Sensor

January 7, 2015 – 5:33 pm | Edit Post
GlySens Raises $12M for Wireless Implantable Glucose Sensor

San Diego-based GlySens says it has raised $12 million in Series C funding to advance its wireless technology for an implantable sensor that could be used to monitor blood sugar levels in people with…

[[Click headline to continue reading.]]

GlySens Raises $12M for Wireless Implantable Glucose Sensor

January 7, 2015 – 5:33 pm | Edit Post

San Diego-based GlySens says it has raised $12 million in Series C funding to advance its wireless technology for an implantable sensor that could be used to monitor blood sugar levels in people with…

[[Click headline to continue reading.]]

GlySens Raises $12M for Wireless Implantable Glucose Sensor

January 7, 2015 – 5:33 pm | Edit Post
GlySens Raises $12M for Wireless Implantable Glucose Sensor

San Diego-based GlySens says it has raised $12 million in Series C funding to advance its wireless technology for an implantable sensor that could be used to monitor blood sugar levels in people with…

[[Click headline to continue reading.]]

Epic Sciences Receives Certification For Its Cancer Diagnostics Laboratory

January 7, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ –Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department…

HUYA Bioscience International Is The First To Leverage Tripartite Cooperation

January 7, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ –HUYA Bioscience International (HUYA) announced today that the Pharmaceutical and Medical Devices Agency (PMDA) has accepted its accelerated development strategy for the novel cancer drug HBI-8000. HUYA is developing HBI-8000 for the treatment of adult T-cell leukemia/lymphoma…